| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5822218 | Antiviral Research | 2014 | 5 Pages |
Abstract
The efficacy of oseltamivir-zanamivir combination therapy compared to that of monotherapy was evaluated in mice infected with influenza A(H3N2) or A(H1N1)pdm09 viruses. For A(H3N2) virus, zanamivir monotherapy and oseltamivir-zanamivir combination showed significant reduction of mean weight loss compared to oseltamivir. Zanamivir monotherapy also conferred decreased mortality, weight loss and lung viral titers (LVT) compared to oseltamivir for A(H1N1)pdm09 wild-type virus. Intermediate benefits were observed for the oseltamivir-zanamivir combination. For the oseltamivir-resistant A(H1N1)pdm09 H275Y virus, the efficacy of oseltamivir-zanamivir was comparable to that of zanamivir and significantly higher than that of oseltamivir in terms of survival, weight loss and LVT.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Andrés Pizzorno, Yacine Abed, Chantal Rhéaume, Guy Boivin,